Evidence map›Paper›PMID 36694116›Full record

ArticleClinical proteomics2023

Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?

Emma Skau, Philippe Wagner, Jerzy Leppert, Johan Ärnlöv, Pär Hedberg

Open access · goldAbstract read
In one paragraph

Article in Clinical proteomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emma SkauCentre for Clinical Research, Västmanland County Hospital, Uppsala University, SE-72 189, Västerås, Sweden. emma.skau@outlook.se.
Philippe WagnerCentre for Clinical Research, Västmanland County Hospital, Uppsala University, SE-72 189, Västerås, Sweden.
Jerzy LeppertCentre for Clinical Research, Västmanland County Hospital, Uppsala University, SE-72 189, Västerås, Sweden.
Johan ÄrnlövSchool of Health and Social Studies, Dalarna University, Falun, Sweden.
Pär HedbergCentre for Clinical Research, Västmanland County Hospital, Uppsala University, SE-72 189, Västerås, Sweden.
Uppsala University · SEDalarna University · SE

Funding

Sparbanksstiftelsen Nya grants 552, 693, 932, and 2297The County of Västmanland grants LTV-239131 and LTV-398881The Swedish Medical Association 2006-18166
6 · The paper itself

Abstract

backgroundWe aimed to compare absolute plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) and growth differentiation factor 15 (GDF-15) obtained by a conventional immunoassay with the corresponding relative concentrations from a proximity extension assay (PEA) and compare the prognostic impact of the protein levels obtained from these assays.

methodsWe evaluated 437 patients with peripheral arterial disease (PAD) and a population-based cohort of 643 individuals without PAD. Correlations were calculated using Spearman's rank correlation coefficients (rho). The discriminatory accuracy of the protein levels to predict future cardiovascular events was analyzed with Cox regression and presented as time-dependent areas under the receiver-operator-characteristic curves (tdAUCs).

resultsFor NT-proBNP, the two assays correlated with rho 0.93 and 0.93 in the respective cohort. The PEA values leveled off at higher values in both cohorts. The corresponding correlations for GDF-15 were 0.91 and 0.89. At 5 years follow-up, the tdAUCs in the patient cohort were similar for NT-proBNP and GDF-15 regardless of assay used (0.65-0.66). The corresponding tdAUCs in the population-based cohort were between 0.72 and 0.77.

conclusionExcept for the highest levels of NT-proBNP, we suggest that PEA data for NT-proBNP and GDF-15 reliably reflects absolute plasma levels and contains similar prognostic information.

Indexed as

BiomarkersGrowth differentiation factor 15ImmunoassayN-terminal pro-brain natriuretic peptidePeripheral arterial diseaseProteomicProximity extension assay

Identifiers

PMID36694116
PMCPMC9872369
OpenAlexW4317820234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.